Skip to content
PharmaManufacturingIQ

Scaling Up Viral Vector Manufacturing – Moving From the Lab to the Clinic

This article explores how starting materials, specifically producer cell lines and the design of transfer plasmids, affect the quality attributes of AAV vectors.

By PharmaManufacturingIQ Staff
Scaling Up Viral Vector Manufacturing – Moving From the Lab to the Clinic
Published: | 7 min read
Share to X Share to Bluesky Share to Facebook Share to LinkedIn Share by email

Sign up to our newsletter

The week's biggest stories from this industry, direct to your inbox.

Personal information